The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients suffering from schizophrenia.
INTRODUCTION
Metabolic abnormalities have consistently been identified as a part of schizophrenic illness (Allison et al., 1999; Homel et al., 2002; Meduna et al., 1942; Raphael, 1921) . The interest in this topic has recently been renewed since the introduction of second generation antipsychotics and their possible association with metabolic abnormalities (Allison and Casey, 2001; Jin et al., 2004; Meyer and Koro, 2004) . The issue of abnormalities in glucose metabolism, in particular diabetes mellitus (DM), has hereby received most attention (De Nayer et al., 2005; Haupt and Newcomer, 2001; Jin et al., 2002 Jin et al., , 2004 Newcomer, 2005; Scheen and De Hert, 2005) .
However, other conditions such as cardiovascular morbidity, abnormal lipid metabolism and obesity also have a serious impact on the physical health of patients diagnosed with schizophrenia. The importance of diagnosing and treating these medical conditions needs to be stressed. Not only is the presence of these conditions associated with a excess mortality rate because of elevated cardiovascular risk (Brown, 1997; Brown et al., 2000; Osby et al, 2000a,b) , it has also been associated with a lower functional outcome (Lyketsos et al, 2002) , a higher prevalence of psychotic and depressive symptoms (Dixon et al., 1999) , a worse perceived physical health (Dixon et al., 1999; Meyer et al, 2005) and lower adherence to medication (Robinson et al., 2002; Weiden et al, 2004 Grundy et al., 2004) . A more recent definition, by the International Diabetes Federation (IDF, 2005) , stressed the importance of waist circumference, using both more stringent and ethnic-/race-specific criteria. Recent research on MetS in the general population has indeed provided evidence for the development of ethnic-/race-specific criteria (Cossrow and Falkner, 2004; Ford et al., 2002; Park et al., 2003; Kraja et al., 2005; Misra et al, 2005; Rakugi and Ogihara, 2005) . Until now, it has remained unclear to what extent these differences in the general population are due to genetic factors or cultural factors such as life style or economic factors.
To evaluate the prevalence of MetS in patients diagnosed with schizophrenia and the impact of life style and economic factors within distinct ethnic groups, prospective large sample studies in different countries are needed. Only few studies on the prevalence of MetS among patients diagnosed with schizophrenia are available. The prevalence of MetS in these studies was around 40% (Basu et al., 2004; Heiskanen et al, 2003) , but limited conclusions can be drawn from these studies because of their limited sample sizes. A large study by Cohn et al. of 240 Canadian subjects revealed a prevalence rate of 42.6% for males and 48.5% for females (Cohn et al., 2004) . These figures are comparable to those found in the CATIE study by McEvoy et al. who found prevalence rates of 36.6% for males and 54.2% for females . To our knowledge, this is the first large sample European study on the prevalence of MetS. In a preliminary report, a prevalence rate of 22% among a sample of 100 patients was found (De Hert et al., in press ). We therefore hypothesized that the prevalence rate of MetS for our sample of 430 schizophrenic subjects would be lower than the US and Canadian prevalence rates found by McEvoy et al. and Cohn et al., respectively.
METHODS
All consecutive patients with a DSM-IV diagnosis of schizophrenia or schizoaffective disorders (18.6%), both out-(28.4%) or in-patients, of a university psychiatric hospital and affiliate services, were asked to participate in an extensive screening and prospective follow-up study of metabolic parameters. The prospective inclusions started in November 2003. At baseline, patients received a full-fasting laboratory screening, clinical measurements and an ECG. A 75-g glucose load Oral Glucose Tolerance Test (OGTT) was performed in a large subsample of patients. Patients were initiated on an overnight fast and were monitored during the OGTT. All laboratory analyses were performed in the same laboratory. The presence of the MetS was assessed using the ATP-III criteria, the adapted ATP-III criteria (AHA; fasting glucose ≥ 100 mg/dl) and the recent IDF criteria. For the diagnosis of diabetes and pre diabetic abnormalities, we used the criteria of The American Diabetes Association [impaired fasting glucose (IFG) ≥ 100 mg/dl and impaired glucose tolerance (IGT), glucose >140 mg/dl at 2 h in the OGTT] (Expert Committee, 1997 Committee, , 2003 .
Descriptive statistics were computed for the basic demographic and clinical variables as well as for the variables relevant for the evaluation of metabolic abnormalities. The influence of the presence/absence of the metabolic syndrome and the presence/absence of glucose abnormalities on continuous variables was assessed by means of an independent samples t-test. The association between categorical variables was evaluated by a Chi-square test (Table 1) .
The study was approved by an ethical committee and all patients gave written informed consent.
RESULTS
The mean age of the patients was 36.5 years (S.D. =11.8) and the mean duration of illness was 13.0 years (S.D. = l0.l). 64.9% of the patients were male. 99% were white and Belgian natives. For 404 of 418 patients in our sample (excluding patients being treated for diabetes, n = 12), an OGTT could be done at baseline. No significant differences in age or sex were found between the patients that were tested and that were not tested.
All patients were treated with antipsychotic medication. On average they received 3.2 (S.D. = 2.0) different medications. Antipsychotics were combined with anticholinergics (15.8%), antidepressants (38.6%), benzodiazepines (33.7%), mood stabilisers (24.6%) and somatic medication (43.2%). 2.3% (12 patients) was being treated for diabetes, 1.9% of patients took a statin (8 patients) and 10.5% (45 patients) took antihypertensive medication.
The majority of patients were treated with only one antipsychotic (87%). 77.2% of this group received a secondgeneration antipsychotic, 9.8% a first-generation antipsychotic. The remaining patients took a combination of 2 antipsychotics. 8.1% combined a first-with a second-generation agent, 4.4% combined 2 second-generation drugs and 0.5% combined first-generation antipsychotics. The overall distribution of antipsychotics was: 16.7% first-generation antipsychotics; 6.6% amisulpride; 0.2% aripiprazole; 16.1% clozapine, 30.3% olanzapine, 11.7% quetiapine and 18.5% risperidone. (46) The prevalence rates of the MetS according to the different definitions in our sample were 28.4% (ATP-III), 32.3% (ATP-III A), and 36% (IDF). The presence of the specific criteria and the number of criteria are shown in Tables 2 and 3 .
The MetS was more prevalent in female patients. This difference was mainly explained by more frequent central obesity. Significantly more female patients were obese (29.1% obese, 22.5% overweight) compared to male patients (14.0% obese, 42.3% overweight) (χ 2 = 22.97, p<.0001). Female patients were significantly more likely to meet the increased waist criterion according either to ATP-III and ATP-III A (χ 2 = 30.51, p<.0001) or IDF MetS (χ 2 = 14.43,p<.000l).
There was a highly significant effect of age on the prevalence of MetS, regardless of the definition used (p<.0001, t-test, respectively, 14.85, 22.01, 30.09) . Patients with the MetS were, on average, 5 years older than patients without the MetS. There was no significant difference in the prevalence of MetS between antipsychotic agents in this cross-sectional analysis. (286) 24.9% (107) 8.6% (37) According to ADA criteria 8.6% of patients met criteria for diabetes, another 24.9% met criteria for prediabetes (20% IFG, 13.3% IGT, either isolated or in combination). The prevalence of the metabolic syndrome was significantly higher in diabetic subjects (ATP-III 83.78%, ATP-III A 86.5%, IDF 83.78%) compared to patients with pre diabetic abnormalities (ATP-III 35.1%, ATP-III A 50.47%, IDF 54.21%) and patients without glucose abnormalities (ATP-III 18.53%, ATP-III A 18.53%, IDF 23.08%). Patients with MetS were more likely to meet criteria for diabetes or pre diabetic abnormalities in all definitions of the MetS applied (df=2, respectively, χ 2 = 75. 22, 90.59 and 72.75,p<.0001) (Table 4 ).
All parameters evaluated in the OGTT (glucose and insulin values fasting, at 30 min, at 60 min and 120 min) as well as HOMA-IR and glycosylated haemoglobin Alc were significantly different between patients with or without the metabolic syndrome regardless of the definition (p<.0001). All values are higher in patients with MetS. Similar highly significant differences were found on all fasting serum lipid values and calculated lipid risk factors for cardiovascular disease (cholesterol, triglycerides, HDL, LDL, NON-HDL cholesterol, CHOL/HDL and LDL/HDL) (p<.0001).
DISCUSSION
Our study on the prevalence of MetS in patients diagnosed with schizophrenia is the largest study on a European schizophrenic population as of today. It confirms the high prevalence of MetS in this population, reaching as much as twice the prevalence of the general Belgian population (Rietzschel et al., 2005) . The age-adjusted MetS prevalence was 12% in this community sample and MetS was almost twice as prevalent in male compared to female subjects (16% vs. 9%). Furthermore, the presence of the MetS was associated with an elevated presence of diabetes and cardiovascular risk factors. The prevalence of diabetes in this population is 3 times higher than in the general population. Therefore, these data clearly demonstrate the need for screening for MetS in patients diagnosed with schizophrenia, as suggested by De Nayer et al. (2005) and Marder et al. (2004) .
As hypothesized, there was a considerable difference in prevalence rates between our study and the CATIE study. Because our sample consisted of mainly white subjects (99%), a comparison is best made with the white subject subsample of the CATIE cohort. Hence, the difference remains considerable. Prevalence rates in our sample using ATP-IIIA criteria were 30.5% for male patients and 35.8% for female patients, compared to 44.4% for white male patients and 58.1% for white female patients in the CATIE study. The explanation for the difference in prevalence rates could well be life style differences in the European vs. the American population. Unfortunately, to our knowledge, no study has specifically handled this issue. Moreover, an important geographical variation of the prevalence rate of MetS within the US population was reported (Ford et al., 2005) , further complicating the interpretation of the difference in prevalence rates, especially since our recruitment of patients was restricted to one site. Nevertheless, estimates in the general population have consistently been lower for European than for US populations (Boulogne and Vantyghem, 2004; Ferreira et al., 2005; Ford et al., 2002 Ford et al., , 2004 Hu et al, 2004) . These findings clearly show the necessity of a careful demographic and symptomatic description and prospective follow-up of different cohorts in distinct areas, in order to determine the influence of life style and genetics to the diagnosis and treatment of MetS.
The current study also has some limitations. First, it is a cross-sectional study. We intent to follow-up this cohort prospectively, in order to assess metabolic changes during the course of the illness and in function of antipsychotic regimes. Second, patient recruitment was restricted to one site, which could have influenced our results, as described above. Third, we failed to include other parameters, such as dietary habits, physical activity level, and schizophrenic and affective symptoms. Future research should address these issues more specifically, in large, multi-site samples and with prospective study designs.
In conclusion, our data confirm the high prevalence of MetS for a European population of patients. Caregivers should carefully monitor and treat metabolic abnormalities in patients diagnosed with schizophrenia.
